secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2026-07-29T20:05:59+00:00
Accession:  0001193125-26-323652
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Q2 net loss $128M; Phase 3 obesity trials fully enrolled; cash $502M
---------------------------------------------------------------------------

- Net loss of $128.0M ($1.10/share) vs $65.6M ($0.58) in Q2 2025; R&D spend $115.8M.
- Phase 3 VANQUISH-1 (4,500 patients) and VANQUISH-2 (1,000) for subcutaneous VK2735 fully enrolled.
- Oral VK2735 Phase 3 trial initiation expected in Q4 2026; maintenance dosing data due Q3 2026.
- Phase 1 trial of amylin agonist VK3019 initiated in Q2 2026 after IND clearance.
- Appointed Hubert Chen, M.D., as CMO; Dorothy Gemmell to board; cash $502M at June 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/0001193125-26-323652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-20260729.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-323652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer